ClinicalTrials.gg
RecruitingNCT04185285Cardio-FRUpdated Oct 22, 2021

Percutaneous Coronary Intervention Registry FRIBOURG

An observational study in Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by University of Freiburg. Recruiting at 1 site in Switzerland. Open to participants aged 17 Years to 120 Years. Per ClinicalTrials.gov, last updated 2021-10-22.

Sponsored by University of Freiburg · Observational

How we know

From the registry’s dates

  • Started May 2015; still recruiting 11 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
17 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.

Planned enrollment
14th of 52
3,000 · median 992
Started
2015
with 7 others
Observational
52 of 177
15 open now
Primary completion
2017-09
later than 0 of 40 live
Registered
129th of 177
by date
Lead sponsor
5 of 177
University of Freiburg

Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 14th largest by planned enrollment of the 52 observational ones that give a count, is one of 8 that started in 2015, is one of 52 observational ones, reaches primary completion later than 0 of the 40 other live ones, and was the 129th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 17 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Coronary Artery Disease with a site in Switzerland, or all of them as a file.
02

Study summary

The registry aims to follow clinically all consecutive patients treated by percutaneous coronary interventions at hospital \& university Fribourg.

03

Conditions studied

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention

Keywords

  • PCI
04

Who can participate

Ages eligible
17 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All comers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All consecutive patients treated by percutaneous coronary intervention at our institution
  • Able to give and willing to participate

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to participate
  • Enable to provide inform consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Interventions

  • DevicePercutaneous coronary intervention, stents
06

What researchers measure

Primary outcomes

  1. Patient-oriented composite endpoints (POCE)

    Academic Research Consortium definition

    Time frame: 2 years

  2. Major Bleeding

    Bleeding Academic Research Consortium definition

    Time frame: 2 years

  3. Patient-oriented composite endpoints (POCE)

    Academic Research Consortium definition

    Time frame: 5 years

  4. Major Bleeding

    Bleeding Academic Research Consortium definition

    Time frame: 5 years

  5. Patient-oriented composite endpoints (POCE)

    Academic Research Consortium definition

    Time frame: 10 years

  6. Major Bleeding

    Bleeding Academic Research Consortium definition

    Time frame: 10 years

Secondary outcomes

  1. all-cause death

    Academic Research Consortium definition

    Time frame: 2 years

  2. any revascularization

    Academic Research Consortium definition

    Time frame: 2 years

  3. any myocardial infarction

    Academic Research Consortium definition

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Cardiology, university Fribourg Medical Center
    Fribourg, 1708, Switzerland
    Recruiting
    • Cook Y. Stephane, MD · Contactstephane.cook@unifr.ch · +41263063800
    • Masset Lea, BSc · Contactlea.masset@h-fr.ch · +41263063800
    • Serban Puricel, MD · Principal investigator
    • Mario Togni, MD · Principal investigator
    • Diego Arroyo, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Sep 2017, 28 months.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 28 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Dec 4, 2019
StartActual
May 1, 2015
Primary completionActual
Sep 1, 2017
CompletionEst.
Sep 1, 2027
Last update
Oct 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04185285
Lead sponsor
University of Freiburg
Responsible party
Stéphane Cook, Prof (Chairman, cardiology, University of Freiburg) — Principal investigator
First posted
Dec 4, 2019
Start date
May 1, 2015
Primary completion
Sep 1, 2017
Completion
Sep 1, 2027 (estimated)
Last update
Oct 22, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion